1. 1. Pitzalis MV, Mastropasqua F, Passantno A, Massari F, Ligurgo L, Forleo C, et al. Comparison between noninvasive indices of baroreceptor sensitivity and the phenylephrine method in post-myocardial infarction patients. Circulation 1998; 97: 1362-1367.
2. 2. Klinear C, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-Iodobenzylguanidine. J Nucl Med 1981; 22: 129-132.
3. 3. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
4. 4. Merlet P, Valette H, Dubois Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471-477.
5. 5. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 2001; 65: 155-160.